Drug repurposing based novel anti-leishmanial drug screening using in-silico and in-vitro approaches

References

• Nuclear and Kinetoplast DNA Replication in Trypanosomatids | Bentham Science.
   Google Scholar
• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Al-Shar'i, N. A., Al-Balas, Q. A., Al-Waqfi, R. A., Hassan, M. A., Alkhalifa, A. E., & Ayoub, N. M. (2019). Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking. Journal of Computer-Aided Molecular Design, 33(9), 799–815. https://doi.org/10.1007/s10822-019-00226-8
   PubMed Web of Science ®Google Scholar
• Arya, H., & Coumar, M. S. (2014). Virtual screening of traditional Chinese medicine (TCM) database: Identification of fragment-like lead molecules for filariasis target asparaginyl-tRNA synthetase. Journal of Molecular Modeling, 20(6), 2266–2213. https://doi.org/10.1007/s00894-014-2266-9
   PubMed Web of Science ®Google Scholar
• Arya, H., Coumar, M. S., & Bhatt, T. K. (2021). Introduction of structural bioinformatics with respect to drug discovery. In T. K. Bhatt & S. Nimesh (Eds.), The design & development of novel drugs and vaccines (pp. 3–9). Elsevier.
   Google Scholar
• Bhatt, T. K., & Nimesh, S. (2021). The design and development of novel drugs and vaccines: Principles and protocols. Elsevier Science.
   Google Scholar
• Bhowmik, D., Jagadeesan, R., Rai, P., Nandi, R., Gugan, K., & Kumar, D. (2020). Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of Leishmania donovani nuclear DNA primase using ligand based virtual screening, docking and molecular dynamics approaches. Journal of Biomolecular Structure and Dynamics, 1–15.
   PubMed Web of Science ®Google Scholar
• Biswas, T., Resto-Roldan, E., Sawyer, S. K., Artsimovitch, I., & Tsodikov, O. V. (2013). A novel non-radioactive primase-pyrophosphatase activity assay and its application to the discovery of inhibitors of Mycobacterium tuberculosis primase DnaG. Nucleic Acids Research, 41(4), e56. https://doi.org/10.1093/nar/gks1292
   PubMed Web of Science ®Google Scholar
• Bray, P. G., Barrett, M. P., Ward, S. A., & De Koning, H. P. (2003). Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends in Parasitology, 19, 232–239.
   PubMed Web of Science ®Google Scholar
• Camacho, E., Rastrojo, A., Sanchiz, Á., González-de la Fuente, S., Aguado, B., & Requena, J. M. (2019). Leishmania mitochondrial genomes: Maxicircle structure and heterogeneity of minicircles. Genes, 10(10), 758. https://doi.org/10.3390/genes10100758
   PubMed Web of Science ®Google Scholar
• Carvalho, S. F. G., Vieira, T. M., Moura, A. P. V., & Andrade, M. C. (2020). Should an intersection between visceral leishmaniasis endemicity and the COVID-19 pandemic be considered? Medical Hypotheses, 144, 110289. https://doi.org/10.1016/j.mehy.2020.110289
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. https://doi.org/10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• Georgiadou, S. P., Makaritsis, K. P., & Dalekos, G. N. (2015). Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. Journal of Translational Internal Medicine, 3(2), 43–50. https://doi.org/10.1515/jtim-2015-0002
   PubMed Web of Science ®Google Scholar
• Gillies, P. S., & Dunn, C. J. (2000). Pioglitazone. Drugs , 60(2), 333–343. https://doi.org/10.2165/00003495-200060020-00009
   PubMed Web of Science ®Google Scholar
• Goto, H., & Lindoso, J. A. L. (2012). Cutaneous and mucocutaneous leishmaniasis. Infectious Disease Clinics, 26, 293–307.
   Google Scholar
• Halgren, T. A. (2009). Identifying and characterizing binding sites and assessing druggability. Journal of Chemical Information and Modeling, 49(2), 377–389. https://doi.org/10.1021/ci800324m
   PubMed Web of Science ®Google Scholar
• Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Krilov, G., Jorgensen, W. L., Abel, R., & Friesner, R. A. (2016). OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, 12(1), 281–296. https://doi.org/10.1021/acs.jctc.5b00864
   PubMed Web of Science ®Google Scholar
• Herwaldt, B. L. (1999). Leishmaniasis. The Lancet, 354, 1191–1199.
   Google Scholar
• Hines, J. C., & Ray, D. S. (2010). A mitochondrial DNA primase is essential for cell growth and kinetoplast DNA replication in Trypanosoma brucei. Molecular and Cellular Biology, 30(6), 1319–1328. https://doi.org/10.1128/MCB.01231-09
   PubMed Web of Science ®Google Scholar
• Hines, J. C., & Ray, D. S. (2011). A second mitochondrial DNA primase is essential for cell growth and kinetoplast minicircle DNA replication in Trypanosoma brucei. Eukaryotic Cell, 10, 445–454.
   PubMedGoogle Scholar
• Jhingran, A., Chawla, B., Saxena, S., Barrett, M. P., & Madhubala, R. (2009). Paromomycin: Uptake and resistance in Leishmania donovani. Molecular and Biochemical Parasitology, 164, 111–117.
   PubMed Web of Science ®Google Scholar
• Kumar, A., Pandey, S. C., & Samant, M. (2018). Slow pace of antileishmanial drug development. Parasitology Open, 4. https://doi.org/10.1017/pao.2018.1
   Google Scholar
• Lanzetta, P. A., Alvarez, L. J., Reinach, P. S., & Candia, O. A. (1979). An improved assay for nanomole amounts of inorganic phosphate. Analytical Biochemistry, 100(1), 95–97. https://doi.org/10.1016/0003-2697(79)90115-5
   PubMed Web of Science ®Google Scholar
• Maltezou, H. C. (2009). Drug resistance in visceral leishmaniasis. Journal of Biomedicine and Biotechnology, 2010
   PubMedGoogle Scholar
• Martínez de Iturrate, P., Sebastián-Pérez, V., Nácher-Vázquez, M., Tremper, C. S., Smirlis, D., Martín, J., Martínez, A., Campillo, N. E., Rivas, L., & Gil, C. (2020). Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 199–210. https://doi.org/10.1080/14756366.2019.1693704
   PubMed Web of Science ®Google Scholar
• Mishra, J., & Singh, S. (2013). Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death. Experimental Parasitology, 135, 397–406.
   PubMed Web of Science ®Google Scholar
• Pandey, R. K., Sharma, D., Bhatt, T. K., Sundar, S., & Prajapati, V. K. (2015). Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: Virtual screening, molecular docking, dynamics and ADMET approach. Journal of Biomolecular Structure & Dynamics, 33(12), 2541–2553. https://doi.org/10.1080/07391102.2015.1085904
   PubMed Web of Science ®Google Scholar
• Pandey, R. K., Verma, P., Sharma, D., Bhatt, T. K., Sundar, S., & Prajapati, V. K. (2016). High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 83, 141–152. https://doi.org/10.1016/j.biopha.2016.06.010
   PubMed Web of Science ®Google Scholar
• Pitt, W. R., Calmiano, M. D., Kroeplien, B., Taylor, R. D., Turner, J. P., & King, M. A. (2013). Structure-based virtual screening for novel ligands. In M. A. Williams & T. Daviter (Eds.), Protein-ligand interactions (pp. 501–519). Springer.
   Google Scholar
• Pulvertaft, R. J. V. (1960). Stages in the life-cycle of Leishmania donovani. Transactions of the Royal Society of Tropical Medicine and Hygiene, 54, 191–192.
   Google Scholar
• Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., Singh, D., & Das, P. (2012). Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrobial Agents and Chemotherapy, 56(2), 1031–1041. https://doi.org/10.1128/AAC.00030-11
   PubMed Web of Science ®Google Scholar
• Rai, P., Arya, H., & Kumar, D. (2021). Protein purification and desalting. In T. K. Bhatt & S. Nimesh (Eds.), The design & development of novel drugs and vaccines (pp. 181–201). Elsevier.
   Google Scholar
• Rai, P., Singh, S., & Nimesh, S. (2021). Biological assay. In T. K. Bhatt & S. Nimesh (Eds.), The design & development of novel drugs and vaccines (pp. 203–210). Elsevier.
   Google Scholar
• Reithinger, R., Dujardin, J.-C., Louzir, H., Pirmez, C., Alexander, B., & Brooker, S. (2007). Cutaneous leishmaniasis. The Lancet Infectious Diseases, 7, 581–596.
   PubMed Web of Science ®Google Scholar
• Ribeiro, N. Q., Santos, A. P. N., Emídio, E. C. P., Costa, M. C., Freitas, G. J. C., Carmo, P. H. F., Silva, M. F., de Brito, C. B., de Souza, D. G., Paixão, T. A., & Santos, D. A. (2019). Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. International Journal of Antimicrobial Agents, 54(3), 301–308. https://doi.org/10.1016/j.ijantimicag.2019.06.020
   PubMed Web of Science ®Google Scholar
• Sarwono, A. E. Y., Mitsuhashi, S., Kabir, M. H. B., Shigetomi, K., Okada, T., Ohsaka, F., Otsuguro, S., Maenaka, K., Igarashi, M., Kato, K., & Ubukata, M. (2019). Repurposing existing drugs: Identification of irreversible IMPDH inhibitors by high-throughput screening. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 171–178. https://doi.org/10.1080/14756366.2018.1540474
   PubMed Web of Science ®Google Scholar
• Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. https://doi.org/10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Sharma, D., Dada, R., Tejavath, K. K., Rai, P., Soni, R., Yaragorla, S., & Bhatt, T. K. (2020). A paradigm towards the antimalarial quest: In silico identification and biological evaluation of novel inhibitors targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase. Journal of Biomolecular Structure & Dynamics, 38(1), 295–301. https://doi.org/10.1080/07391102.2019.1570342
   PubMed Web of Science ®Google Scholar
• Sundar, S. (2001). Drug resistance in Indian visceral leishmaniasis. Tropical Medicine & International Health : TM & IH, 6(11), 849–854. https://doi.org/10.1046/j.1365-3156.2001.00778.x
   PubMed Web of Science ®Google Scholar
• Sundar, S., & Chatterjee, M. (2006). Visceral leishmaniasis-current therapeutic modalities. Indian Journal of Medical Research, 123, 345.
   PubMed Web of Science ®Google Scholar
• Tekin, S., & Hansen, P. J. (2001). Use of the Bradford protein assay in a microtiter plate format. Department of.
   Google Scholar
• Turner, P. (2005). XMGRACE, version 5.1. 19. Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology.
   Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• van Griensven, J., & Diro, E. (2012). Visceral leishmaniasis. Infectious Disease Clinics, 26, 309–322.
   Google Scholar
• WHO. (2016). Leishmaniasis.
   Google Scholar
• Zijlstra, E., Musa, A., Khalil, E., El Hassan, I., & El-Hassan, A. (2003). Post-kala-azar dermal leishmaniasis. The Lancet. Infectious Diseases, 3(2), 87–98. https://doi.org/10.1016/S1473-3099(03)00517-6
   PubMed Web of Science ®Google Scholar